This marks another groundbreaking year of progress for patients with melanoma. The approvals of new therapies, whether alone or in combination with others, underscore the tremendous advancements in treatment options that simply did not exist for patients just a few years ago. In the last five years, the FDA has approved 11 new therapies to treat melanoma. To put that in perspective, when we started MRA eight years ago, there were only two approved treatments. It’s truly an unprecedented rate of progress.

As we usher in fresh approaches to attacking cancer, melanoma research continues to lead the way. Scientists are using immunotherapies – pioneered to treat melanoma – to tackle myriad types of cancers. In addition to new checkpoint blockade treatments, one of the new therapies approved for melanoma in the last year was a cancer-fighting virus that is injected directly into the tumor. It’s the first approval of its kind and could signal an entirely new approach to cancer treatment.

At MRA, we continue to push the bar higher to further our understanding of melanoma, with a focus on prevention, diagnosis, and treatment. With our latest grant cycle, we have committed nearly $68 million to melanoma research. Combined with our leveraged funding, we’ve applied more than $148 million to date to fund melanoma research.

People with melanoma have so many more options than they did just a few years ago, yet for too many people, these treatments are just not enough. We have much work left to do to increase our understanding of the disease and effectively develop and enhance therapies to treat melanoma. Through our leadership and deep commitment to funding the top research and incentivizing the brightest minds into the field, MRA is poised to help propel the melanoma research community into the next phase.

Highlighted in this report are some of our accomplishments from the last year, which underscore our critical role in building partnerships, fostering collaboration, and advancing the field of research. We are grateful to the many individuals, organizations, government leaders, and companies whose support has enabled us to get to this point. We look forward to working together to celebrate more accomplishments and see a day when we defeat melanoma.

Debra Black
Chair and Co-Founder

Margaret Anderson
Acting President and CEO
“Many of the paradigms that are the guideposts now for using immune-based drugs for any kind of cancer were established first in melanoma. A lot of the work about treatment resistance in both immunotherapies and targeted therapies were funded by MRA grants, and it’s one of the areas where MRA has really played a leadership role.”

Suzanne L. Topalian, M.D.
Director of the Melanoma Program, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University
MRA Board of Directors
The mission of the Melanoma Research Alliance (MRA) is to end suffering and death due to melanoma by collaborating with all stakeholders to accelerate powerful research, advance cures for all patients, and prevent more melanomas.

Founded in 2007 by melanoma survivor Debra Black and her husband, Leon, under the auspices of the Milken Institute, MRA has ushered in a dynamic new era of scientific progress. MRA has become the largest private funder of melanoma research, funding nearly $68 million in cutting-edge studies and leveraging millions more from other sources. Thanks to the generous support of our founders, 100 percent of donations to MRA directly support our research program.

About MRA

Our Research Strategy:

Funding the Best and Growing the Field
MRA applies rigorous standards to its grant process, backed by a world-class peer review process. MRA has funded 238 Principal Investigators (PIs) at 99 institutions in 14 countries. Our Young Investigator Award program, which attracts and supports the next generation of melanoma research leaders, has funded 74 bright, early-career scientists.

Focusing on Team Science
Team Science Awards, which fund multidisciplinary research groups, often across institutions and researchers of varying levels of seniority, account for 63 percent of research funding to date.

Accelerating New Treatments
Within our research portfolio, 89 percent of funding is directed at melanoma treatment science, including 21 clinical trials and 48 treatment approaches supported. MRA funding has supported studies of every melanoma treatment approved from 2011 to now, including agents prior to their FDA approval.

Fostering Collaboration
As a trusted voice in the melanoma field, MRA brokers innovative collaborations with stakeholders in industry, academia, and the nonprofit sectors, cultivating additional support for high-impact translational research.
Funded to Date:

Team Science Awards fulfill one of MRA’s primary goals—to foster a collaborative research process. Multidisciplinary teams consist of Principal Investigators with complementary expertise, often from multiple different institutions around the globe. Team science projects promote transformational melanoma research advances with the potential for rapid clinical translation.

Established Investigator Awards support investigators with an established record of scientific productivity and accomplishment and who are past the initial four years of their first academic faculty appointment.

Young Investigator Programs aim to attract early-career scientists with novel ideas into melanoma research, thereby recruiting and supporting the next generation of melanoma researcher leaders. Young Investigators are scientists within four years of their first academic faculty appointment. A mentorship commitment from a senior investigator is required.

Pilot Awards fund potentially transformative ideas that do not have extensive preliminary data but articulate a clear hypothesis and translational goals. Resources for such “high-risk, high-reward” projects are important to establish proof-of-concept, which may then leverage additional funding through more traditional avenues. Development awards are a subtype in which one year of funding is provided.

Academic-Industry Partnership Awards are designed to facilitate interactions between the academic and industrial research sectors, and are co-supported by MRA and an industrial partner that matches or exceeds MRA’s funding and whose involvement is essential to the project.

Science

MRA was founded to help initiate the development of new therapies for patients with melanoma and expedite the pace of scientific discovery. Our research portfolio represents the cornerstone of our efforts to do just that.

The outlook for patients with advanced melanoma is much more promising than it was just a few years ago. In fact, since MRA’s founding, 11 new therapies have been approved by the FDA for melanoma. These therapies include molecularly targeted treatments, immunotherapies, and a combination of these approaches.

MRA’s funded research is yielding critical insights that will improve current therapies by:

- Identifying new biomarkers
- Combining treatments aimed at countering drug resistance
- Discovering new and more effective drug targets

In addition, MRA is playing a key role in new prevention and early detection efforts.
Investing in Immunotherapy

Beginning in 2011, the first new melanoma treatments in several decades were approved by the FDA. In 2011, ipilimumab was approved by the FDA and stands as the first checkpoint-blocking antibody drug and the only anti-CTLA-4 agent available. In 2014, the FDA approved a newer class of immune checkpoint antibodies, pembrolizumab and nivolumab, that block a protein called PD-1. Additional melanoma treatments continued to come in 2015, including the first combination immunotherapy (nivolumab and ipilimumab), as well as the first oncolytic viral therapy, TVEC, and the first use of checkpoint blockade in the adjuvant, post-surgical, setting.

MRA immunotherapy research has been central to advancing the field of immune checkpoint blockade, with more than $26 million in support from MRA for immunotherapy research since 2008.

Advancing Targeted Therapy

When the first new melanoma treatments in several decades were approved by the FDA in 2011, one of those treatments was a targeted therapy known as vemurafenib. Vemurafenib is used for patients diagnosed with a specific mutation (V600E) in a gene known as BRAF. Alterations in the BRAF gene are implicated in more than half of all melanomas, making it an important therapeutic target. Targeted drugs that disable BRAF signaling exert profound responses in some patients, but resistance is a significant challenge. Through the Stand Up 2 Cancer-MRA Melanoma Dream Team and other projects, MRA-funded investigators are researching different factors that influence resistance to treatment.

MRA has invested $35 million in research to improve existing and advance new targeted therapies for melanoma.

What’s Next

- **MRA** funded researchers are focused on identifying mechanisms of resistance as well as combinations and new therapies to improve outcomes.

Collaboration to Amplify Our Impact

- **With Industry**
  - MRA is supporting 14 Academic-Industry Partnership Awards in conjunction with matched support from an industry partner.
  - **With Institutions**
    - MRA is collaboratively funding 21 awards with academic institutions, a model that expanded significantly in 2015.
  - **With Foundations**
    - MRA has co-funded 11 research projects with premier cancer research foundations.

MRA Chief Science Officer Louise M. Perkins, Ph.D., center, leads a panel discussion at the 2015 Milken Institute Global Conference.

What’s Next

Our funded researchers are focused on understanding the mechanisms underlying therapeutic response and resistance, identifying treatment-related biomarkers, and developing combinatorial therapy approaches.
International Collaboration
Shedding Light on Tumor Growth to Offer New Avenues for Therapeutic Intervention

The chemical signals that tell cancer cells to metastasize, or spread to other parts of the body, are often activated during the earliest stages of tumor development. One of the limitations for the design of new drugs for cancer, particularly in melanoma, is the inability to monitor these metastatic cells. With support from an MRA Team Science Award, Maria Soengas, Ph.D., of the Spanish National Cancer Research Centre, and an international group of scientists are developing novel tools and agents that target the process by which melanoma induces the formation of vessels for dissemination. Thus far, they have developed a new way of imaging vessel activity in unprecedented detail, identified new patterns of melanoma metastasis, and uncovered new functions of melanoma “exosomes” (small vesicles that are found in the blood). Ultimately, the investigators hope to provide the melanoma community with new tools and information to enable better diagnosis and treatment.

Maximizing Current Treatments
Exploring Novel Combination Therapies to Expand Melanoma Treatment Options

Tumors use several tactics to actively interfere with the immune system’s response to cancer. Thus, uncovering these multiple mechanisms should reveal which treatments should be explored in combination to target them. Duke Cancer Institute’s Brent Hanks, M.D., Ph.D., recipient of the Duke-MRA Young Investigator Award in Honor of Frank Courtney, is investigating one way in which tumors interfere with the immune system that involves the production of an immune-suppressive factor known as transforming growth factor-beta (TGF-beta). His laboratory has found that a drug targeting TGF-beta improves the efficacy of the FDA-approved melanoma drug ipilimumab in pre-clinical models. Importantly, they have identified the biological mechanisms that underlie these results. The findings suggest that combining these drugs is a promising approach that should be investigated further in clinical trials.

Benefits Beyond Melanoma
“Bedside-To-Bench” Research to Improve Treatment for Patients with Brain Metastases

Melanoma has an extremely high propensity to spread (or metastasize) to the brain, after which patients have exceedingly limited treatment options. Lung cancer has the highest incidence of brain metastases among all cancers. One of the most promising approaches to treating cancer involves drugs that boost the immune system’s ability to kill cancer cells, such as the PD-1 inhibitors that have recently come onto the market for melanoma and lung cancer. These therapies have not been well studied in patients with active brain metastases, and little is known about whether the immune system can reject cancer cells there.

To address these questions, Lucia Jilaveanu, M.D., Ph.D., at Yale University, with support from a Young Investigator Award funded by MRA in collaboration with the Lung Cancer Research Foundation and LUNGevity, is currently studying samples collected in a Phase 2 study of PD-1 therapy in melanoma and lung cancer patients with brain metastases to identify biomarkers that may predict responses to therapy. While patient accrual for the trial is ongoing, preliminary results indicate that pembrolizumab has promising activity in the brain in these cancers.

Since its launch MRA funding has resulted in:

- 21 Clinical trials to test new melanoma treatments
- 28 Patent applications filed for new research and treatment technology
- 180 Projects supported to advance melanoma research worldwide
- 238 Principal investigators conducting translational melanoma research
Innovation in Action: Collaborative Funding Model

Three years ago, MRA began pioneering a novel collaborative funding program with academic institutions around the world to pursue matched support for scientifically meritorious research that falls outside MRA’s full funding pay line. Through this vehicle, MRA can stretch its resources to support a greater number of research projects, engage new donors in MRA’s work, recruit melanoma researchers, and encourage the growth of institutional melanoma programs. MRA introduced the model in 2013 through a partnership with Duke University to fund a Young Investigator Award. Since then, MRA has greatly expanded the program to involve 21 academic institutions.

As a result of these efforts, MRA has raised approximately $4.2 million for melanoma research projects that would have otherwise not received support. MRA strives to continue to shepherd this program around the world, demonstrate the capacity to co-fund through this novel mechanism, and improve and adjust it year after year.

Scientific Retreat

Each year, MRA convenes its Annual Scientific Retreat, an invitation-only meeting bringing together approximately 300 thought leaders in the field from all sectors to share early research findings, identify future directions, discuss ideas, and develop synergies and partnerships. Catalyzed by MRA’s unique model of assembling and engaging the field’s leaders, the event emphasizes the importance of cross-sector collaborations to advance the melanoma field. The 7th Annual Scientific Retreat was held in Washington, DC, in February 2015.
Awareness and Support

MRA collaborates with like-minded corporations to extend its messaging of awareness and education to the public at large and generate critical resources for its melanoma research program. Aligning with MRA to develop socially responsible campaigns also enables companies to achieve their financial goals while increasing exposure to new audiences.

With access to the most prominent thought leaders in the field, MRA is a trusted source of content, including the most recent scientific data and news and a growing supply of patient-oriented resources. MRA functions as a catalyst for productive partnerships between its network of corporate allies and the melanoma research and advocacy communities.

“The options were far fewer even a year ago” for patients such as Carter, said Louise Perkins, chief science officer for the Melanoma Research Alliance, the largest private funder of melanoma research. “These latest immunotherapy drugs, whether alone or in combination with other treatments, seem to be the future of cancer therapy.”

**The Washington Post**
August 20, 2015

“The ‘BREAKTHROUGH’ DRUG JIMMY CARTER IS TAKING TO TREAT HIS CANCER”

For the fifth year in a row, Sports Authority executed a round-up at checkout program in stores during the month of May, generating nearly $300,000 for MRA, bringing the total raised over five years to nearly $1.2 million. The campaign took place in Sports Authority stores across the US and expanded to Puerto Rico this year for the first time. Stores housed important educational information about the risks associated with melanoma and recommendations on how shoppers can protect their skin.

Neiman Marcus Camp Gorgeous

On the heels of Melanoma Awareness Month, Neiman Marcus partnered with 17 luxury beauty brands during its annual Camp Gorgeous promotion, which features the summer’s must-have beauty essentials. The participating brands, whose products include SPF skincare items, self-tanners, and sunscreens, donated 10% of the net proceeds to MRA. As a statement of support, Neiman Marcus matched their donations dollar-for-dollar, raising $100,000 in total.

L’Oréal Paris #ItsTHATWorthIt Campaign

Throughout the summer months, L’Oréal Paris’ It’s THAT Worth It campaign encouraged people to share images and videos using SPF or sunless Tanner to protect their skin. For every social share, L’Oreal Paris donated $1 to MRA, up to $250,000.

Lands’ End

During the summer, Lands’ End designed an exclusive Melanoma Research Alliance monogrammed tote with essentials for the family including two UPF 50 swim tees, a beach blanket, and scarf, with 10% of the tote proceeds benefiting MRA. In conjunction with the tote promotion, Lands’ End also launched a social media campaign asking followers to post photos tagged with #LandsEndSunSavvy showing how they stay safe from the sun’s rays.

Radiant Fluid Foundation SPF 24
Clé de Peau Beauté
Super Fluid UV Defense SPF 50+
Kiehl’s Since 1851
Ultra Sun Protection Sunscreen SPF 50
Chantecaille
Fresh
SugarLip Treatments Sunscreen SPF 15
Continuous Mist Sunscreens
Hampton Sun
Kate Somerville
360° Tanning Towelettes
Le Métier de Beauté
Peau Vierge Anti-Aging Complexe SPF 18
The Broad Spectrum SPF 50 UV Protecting Fluid
La Mer
Lancôme Paris
Absolue Premium Bx Replenishing and
Rejuvenating Day Cream SPF 15
The Cure Sheer Oil-Free Fluid SPF 20
Natura Bissé
Laura Mercier
Foundation Primer - Protect SPF 30
Complexion Perfector BB SPF 20
Omorovicza
Tom Ford
Ultimate Sun Protection Lotion SPF 50+
Shiseido
Sisley-Paris
Sunleÿa Age Minimizing Sun Care
RéVive
Dark Lotion Absolute Luxe
Xen-Tan
Fermitif Neck Renewal Cream SPF 15
Sunscreen Cream SPF 50+
*The MRA name and logo are used with its permission which in no way constitutes an endorsement, express or implied, of any company or product.

*The options were far fewer even a year ago” for patients such as Carter, said Louise Perkins, chief science officer for the Melanoma Research Alliance, the largest private funder of melanoma research. “These latest immunotherapy drugs, whether alone or in combination with other treatments, seem to be the future of cancer therapy.”

For the fifth year in a row, Sports Authority executed a round-up at checkout program in stores during the month of May, generating nearly $300,000 for MRA, bringing the total raised over five years to nearly $1.2 million. The campaign took place in Sports Authority stores across the US and expanded to Puerto Rico this year for the first time. Stores housed important educational information about the risks associated with melanoma and recommendations on how shoppers can protect their skin.

Neiman Marcus Camp Gorgeous

On the heels of Melanoma Awareness Month, Neiman Marcus partnered with 17 luxury beauty brands during its annual Camp Gorgeous promotion, which features the summer’s must-have beauty essentials. The participating brands, whose products include SPF skincare items, self-tanners, and sunscreens, donated 10% of the net proceeds to MRA. As a statement of support, Neiman Marcus matched their donations dollar-for-dollar, raising $100,000 in total.

L’Oréal Paris #ItsTHATWorthIt Campaign

Throughout the summer months, L’Oréal Paris’ It’s THAT Worth It campaign encouraged people to share images and videos using SPF or sunless Tanner to protect their skin. For every social share, L’Oreal Paris donated $1 to MRA, up to $250,000.

Lands’ End

During the summer, Lands’ End designed an exclusive Melanoma Research Alliance monogrammed tote with essentials for the family including two UPF 50 swim tees, a beach blanket, and scarf, with 10% of the tote proceeds benefiting MRA. In conjunction with the tote promotion, Lands’ End also launched a social media campaign asking followers to post photos tagged with #LandsEndSunSavvy showing how they stay safe from the sun’s rays.

Radiant Fluid Foundation SPF 24
Clé de Peau Beauté
Super Fluid UV Defense SPF 50+
Kiehl’s Since 1851
Ultra Sun Protection Sunscreen SPF 50
Chantecaille
Fresh
SugarLip Treatments Sunscreen SPF 15
Continuous Mist Sunscreens
Hampton Sun
Kate Somerville
360° Tanning Towelettes
Le Métier de Beauté
Peau Vierge Anti-Aging Complexe SPF 18
The Broad Spectrum SPF 50 UV Protecting Fluid
La Mer
Lancôme Paris
Absolue Premium Bx Replenishing and
Rejuvenating Day Cream SPF 15
The Cure Sheer Oil-Free Fluid SPF 20
Natura Bissé
Laura Mercier
Foundation Primer - Protect SPF 30
Complexion Perfector BB SPF 20
Omorovicza
Tom Ford
Ultimate Sun Protection Lotion SPF 50+
Shiseido
Sisley-Paris
Sunleÿa Age Minimizing Sun Care
RéVive
Dark Lotion Absolute Luxe
Xen-Tan
Fermitif Neck Renewal Cream SPF 15
Sunscreen Cream SPF 50+
*The MRA name and logo are used with its permission which in no way constitutes an endorsement, express or implied, of any company or product.

*The options were far fewer even a year ago” for patients such as Carter, said Louise Perkins, chief science officer for the Melanoma Research Alliance, the largest private funder of melanoma research. “These latest immunotherapy drugs, whether alone or in combination with other treatments, seem to be the future of cancer therapy.”

For the fifth year in a row, Sports Authority executed a round-up at checkout program in stores during the month of May, generating nearly $300,000 for MRA, bringing the total raised over five years to nearly $1.2 million. The campaign took place in Sports Authority stores across the US and expanded to Puerto Rico this year for the first time. Stores housed important educational information about the risks associated with melanoma and recommendations on how shoppers can protect their skin.

Neiman Marcus Camp Gorgeous

On the heels of Melanoma Awareness Month, Neiman Marcus partnered with 17 luxury beauty brands during its annual Camp Gorgeous promotion, which features the summer’s must-have beauty essentials. The participating brands, whose products include SPF skincare items, self-tanners, and sunscreens, donated 10% of the net proceeds to MRA. As a statement of support, Neiman Marcus matched their donations dollar-for-dollar, raising $100,000 in total.

L’Oréal Paris #ItsTHATWorthIt Campaign

Throughout the summer months, L’Oréal Paris’ It’s THAT Worth It campaign encouraged people to share images and videos using SPF or sunless Tanner to protect their skin. For every social share, L’Oreal Paris donated $1 to MRA, up to $250,000.

Lands’ End

During the summer, Lands’ End designed an exclusive Melanoma Research Alliance monogrammed tote with essentials for the family including two UPF 50 swim tees, a beach blanket, and scarf, with 10% of the tote proceeds benefiting MRA. In conjunction with the tote promotion, Lands’ End also launched a social media campaign asking followers to post photos tagged with #LandsEndSunSavvy showing how they stay safe from the sun’s rays.
Fundraising Events

Leveraged Finance Fights Melanoma

On May 19, 2015, nearly 1,000 people from the leveraged finance community gathered at Rockefeller Center to support MRA, with Carl Icahn serving as keynote speaker. This fourth annual event raised more than $1.5 million for MRA’s research portfolio. In support of early detection, hundreds of attendees also pledged to get a skin check within the next six months.

Benefit Dinner Hosted by Sotheby’s

On October 29, 2015, supporters of MRA raised $5.8 million to fund world-class melanoma research at this fourth biennial benefit dinner. Set against the backdrop of Sotheby’s New York art collection, the pinnacle of the evening was the live auction of Young Investigator Awards, which aim to attract the brightest minds and innovative research to the field of melanoma research.
Education and Outreach

FDA Briefing

In June, MRA spearheaded a briefing with FDA leaders involved in approving new products and diagnostics to update them on the latest clinical research news and challenges for the melanoma community. MRA’s scientific staff were joined by members of the Medical Advisory Panel to provide an overview of the current landscape.

Patient Education and Engagement

With the pace of scientific discovery evolving rapidly, patients with advanced melanoma are now faced with many treatment options – a welcome change from just a few years ago. Yet with all the change comes a lot of uncertainty about the best course of treatments, so MRA has continued to provide unbiased information on the latest therapies and treatments in development. With the goal of arming patients and caregivers with information to take an active role in their care, the patient engagement activities aim to translate the complex, scientific advances into easily understood, actionable information for patients.
<table>
<thead>
<tr>
<th>Amount Range</th>
<th>Donors and Supporters</th>
</tr>
</thead>
</table>
$5,000-$9,999
Catherine and Christopher Abbate
AEG Live
John Albert
Anchorage Capital Group
Shayyr Aziz
Berkshire Partners LLC
BNP Paribas
CIFC Asset Management LLC
COOLA
Credit Agricole
Debevoise & Plimpton LLP
Jeanne Deepsalque Salvatore and Louis Salvatore
Kathryn and Philip Dunn
Tom Keys and Keith Fox
Freedom Mortgage
Scot French
Jack Frost
Greenberg Traurig, P.A.
Rhonda and Stratton Heath
Christy Hedges
Katherine Boden Holland and David Christy Hedges
Rhonda and Stratton Heath
Greenberg Traurig, P.A.
Jack Frost
Scot French
Freedom Mortgage

$1,000-$4,999
Elleen Alexanderson
Ashland, Inc.
Mark Basile
Valdim Berman
Carole Black
BRELLI
Timothy Breadbent
Elizabeth and Christopher Butler
The Cancer Support Community
W. Jane and Simon Canning
Kirsten and Didric Cederholm
City National Civic
City Sarasota
Bradley Cuddick
Anne Dickerson
Andrew Dragoumis
Durham Performing Arts Center
Ertogen, Inc.
Eric Javits, Inc.
Mary Faulkner
Eric Javits, Inc.
Entrogen, Inc.
Durham Performing Arts Center
Andrew Dragoumis
Durham Performing Arts Center
Ertogen, Inc.
Eric Javits, Inc.
Mary Faulkner
First Aid Beauty, LTD
Fondi and David Frieder
GA Association of Regional Commissions
Gas South
William Gates
Peter Glaser
Richard Gold
Dev Gopalani
Greek Theater
Mary and Meyer Grinberg
Lauren Hannahan
Renee Harbers and Chris Liddel
Henry A. Fox Sales Co.
Stephen Hickey
Wanda and Richard Hurd
J. Crew
JADS International
Srinivas Jadadikhi
The Jamie Trust
Paige Jansen
Mara and Jason Kaner
D. Scott Katsaras
John Kigallon
Dawn and Tim Killenberg
Nancy and Albert Kotte
Christopher Kovil
Adam Kurzer
Manza and Alan Lee
Greg Levi
Live Nation Worldwide, Inc.
Peter Mary
MD Solarsciences Corp.
Meryl and Robert Meltzer
Madeleine Mullen Foundation Inc.
NACO
National Philanthropic Trust
Angela Nazarian
Carol Nebel
New York Island Hockey Club
Processing
Alexander Pankov
Christian Panagot-Reustor
Lisa Perkes
Brit Gardens
Francisco Pinto-Leite
Robert Rahr
Red Mountain Entertainment
Ellen and Bruce Ressler
Kimberly and Jeffrey Rosen
William Ruthkoske
Sanger Theatre
Richard Schlosberg
David Scudellari
Wendy and Michael Selig
Shetlar Foundation
Carolyn Shields
Slack Incorporated
SMSC Gaming Enterprise
Soaring Eagle Casino Resort
Starshy Somaya
Starwyn and William Stark
State Fair Commission
Russell Thomas
Time Inc. instyle
Travelers
UBS Realty Investors LLC
Verizon Wireless Amphitheatre
Encore Park
Wagner Family Foundation
Andrew Waldberg
Carol & Michael Weisman Family
Charitable Trust
Jennifer Whitman
Ronan Wicks
Scott Williams
Stan and Louise Wilson
Wagner Family Charitable Trust
Wagner Family Foundation

$1,000-
Anonymous
Kevin Abel
Ashley Abercrombie
Cynthia Abrams
Carol Abrams-Trueba
Active Network
Sanford Anderson
Chelsea Adams
Iritaz Ahmad
Natalie Ahn
Leavitt Abrams
David Allen
John Allen
Nancy and D. Ray Allgood
Amazon Talent Assessment
AMC Networks Inc.
Greg Amici
Douglas Apicella
Diane Archer
Charlotte Aryan
Arts Center Enterprises
Ayse Aruch
Rebecca Asche
Ronna and Dan Askin
Athens CVB
David Austin
Boyd Austin
Debra Autrey
Anne and H. Wood Bacon
Carol and Paul Baker
Christian Bailey
Chellah and Cecil Bailey
Carol and Paul Baker
Richard Baker
Andy Babber
Robert Barnes
Juanita Barnes
Brian Zelin
Richard Zogheb
The Brooks Group and Associates, Inc.
Supporters & Financials

Nadine Broomhead
Beth Brown
Toni Brown
Janet Bryson
C. and L. Buckley
Shirley and Ronald Bugos
A. Robert Buonanno
Tori Burnfield
Helen Burke
Gal Burke
Dana and Ross Burke
Elizabeth Burke
Christopher Burns
Lora and Max Burns
Karlene and David Burris
Suzanne Button Meneses
Angela Buziak
Timothy Cahalan
Susie and Barrett Callaghan
Jim Callaghan
Christine and James Campbell
Cynthia Campbell
Sara Caniglia
April Carberry
Carrie Carbone
Lee Carder
Dana Carey
Yvonne and David Carmichael
Steven Carniol
Neil Carter
Matt Cate
Caughlin & Gerhart LLP
CBIZ Insurance Services, Inc.
Richard Cecil
CPP Pharmacy
Aaron Chant-Powers
Lynda Charow
Matthew Chartrand
Simone Cho
Sarah Choi
Peter Chomyonyk
Rodney Christo
Mark Cicirelli
CJ Perry & Associates
James Clark
Jay Clayton
Rusty Cline
Glenda Colesford
Douglas Cohen
Lawrence Cohen
Julie and John Cohen
Andrew Colao
Lisa Cole
Shih-Lin Coleman
Joye Coley
Lori Collet
Jill Colley
Peter Commons
Judith Connor
Diane Cook
Cece Corbin
Edward Corleschi
Michelle and Randy Corley
Christine Corrigan
Craig Cortright
William Costa
Helene Cotty
Kay and Charles Cox
Maria and Bernie Craig
Patricia Craig
Edward Crook
Ron Cross
Suzanne Cross
William Crowe
Brian Crowell
Massiel Cruz
Elizabeth Curley
Bradley Curney
Sheryl Dallas
Becky Daugherty
Christopher Daur
Melvin Davis
Michel Davis
Piper Davis
Margot Dawkins
Danielle Delfino
Steven Denoncourt
Pam Depace
Troy Dersa
Ptyrules and Raymond Derossi
James Dickens
Alan Dickerson
Jeff Dils
Larry Dix
DLA Piper
Lina Dimitrov
Daniel Dolos
Janet and Brad Donaldson
Irene and Edward Dowdall
DTSC Inc.
Cecila Ducharme
John Duggan
James Dunlap
Craig Dunn
James Durrett
Todd Edwards
Mike Eisthorn
Dorothy and Wayne Eister
Ann Elsworth
Kevin Emerson
Stephen Emery
Beth English
Andrea Erwin
Jean and Al Esposito
Winfried Scott Essex
Gail Evans
Anne Falvey
Wendy Farcone
William Farrell
Tara Farrell-Gartke
Ellen and Frederick Favors
Jim Fieley
Richard Firsten
Leah and Gerald Fitterstein
Thomas FitzGibbon
Ingen Fitzhugh
Lauren Flanen
J. Thomas Flynn
Querlin Franco
Danek Freeman
James Fuhrman
Noelle Fuller
David Furley
Beth Galletti
Kathryn and Mark Gannon
Esther Garbe
Esther Garces
Daniel Garcia
Joan P. Garner
Sarah Gehring
Amy Gensler
Michael Gerber
Sharyn and Walter Gertz
Sharon and Michael Gertz
Barbara Ghoz
Kelleen Gambertone
Jim Gibbs
Lori Gibson
Lisa Giedler
Margaret Gilley
P. C. and Jerome Ginzburg
Laura Glenn
Brian Goldberg
Judy Goldman
Kate Goldsmith
Natalie Goldsmith
Craig Goldstein
Michael Goldstein
Victoria and Tom Goodman
Jonathan Gottfried
Michael Graham
Paty and Robert Graves
Barbara Grenawalt
Nicole Greenblatt
Jeffrey Greer
Brenton Greer
Brenton Greer
Brenton Greer
Brenton Greer
Brenton Greer
Brenton Greer
Brenton Greer
Jason Eldoff
Stephen Rehm
Patty and John Rigby
Catlin Riley and Harsha Murthy
Jeanne and William Riley
Steven Ritterie
James Roschen
Sarah Robertson
Johnna Robinson
Quint Robinson
Ed Roehm
William Romani
Robyn Roof
Rosalind Rosevelt
Marybeth Ross
Jacqueline and Nick Rothenberg
Todd Rothman
Stacy Rotner
Joseph Rowbottom
Crystal Rowden
Ola Rosenfeld
Gina and Carter Rude
Mike Ryan
Robert Ryan
Mark Sarrit
Barbara Sanders
Geri and Neal Sanderson
Michael Sanderson
Paul Sandoli
Gene and Martha Sansalos
Joanna Scales
Rose Scavnaglone
Marie and Robert Scheuermann
Audrey and Scott Scheewe
Marc Schmeideau
Thomas Schubbe
Marla and Douglas Schubert
Craig L. Schwall
Ezra Segal
Carol Shapoff
Paul Sharkey
Maureen Shaughnessy
Maryann and William Sheeley
Holly Sheffield
Daniel Shirley
Sidley Austin LLP
Ashley Siebert
Edward Siegel
Paul Sigfusson
Michael Silver
Ruthie and Arthur Silver
Craig Simmons
Lisa Simms
Linda Simon
Alex and Jo Simpson
Lille and Jeff Sinyard
William Skinner
Sara Skolijak
Bill Slaughter
Bram Smith
Allison and Bob Smith
Frank Smith
John Smith
Sylvia Smith
Josephine Soliano
Christopher Solomon
Mancia and Mel Solomon
Sue and Tom Souls
Sue Souls
Lee and Lew Spasiano
Barbara and Richard Speer
Kendrea and Gary Spencer
Christine Sperling
The Standard
Sarah Stasnyn
Thomas Steih
Steve Schwartz Associates, Inc.
Sean Stevens
Jeanine and Mike Stewart
Donna Stilwell
Helen Stone
Kathryn Storm
The Strand Magazine
Karen Streich
David Strickland
John and Shen Strimp
Sucherman Consulting Group
Craig Sullivan
Margaret and Daniel Sullivan
Margaret Sung and Michael Schmidtberger
Eric Tam
Donna Tanaka
Amy Tanner
Joanne Tanous
Sri Harsha Tata
Steve Taylor
Kim Templin
Morton Tenzer
Texas Destination Imagination
Seana Thomas
Emma Thomas
David Thompson
Valerie Thompson
Bill Thornton
Mark Thornton
Thrivent Financial
Linda Tischler
Janice Tittle
Matthew Toboroff
Mary and Robert Torone
Kreanna Toth
Toys R Us
Janice and David Tranberg
Yvonne and Billy Trapnell
Jeremy Traska
Trend Publications
Joe and Dale Trott
Anna and Keith Trumit
Adam Trupp
David Tudor
Rhett Turner
David Uhman
Jane and Peter Vanderzee
James Vanek
Jamie Vaughn
Peter Vecchio
Lauren Vento
Regina and John Vesty
William Villari
Victor Vilegas
Chris Villenes
Alexander von Perlaff
Allison and Ray Vuitch
Ernest Wakah
Kenneth Walden
Tom Hien-Chieh Wang
Kathy Wang
Brigitte Wang
Andrew Waranch
Ryan Ward
Lisa Wardell
Mary and Phil Warner
John Watson
Rita Wayco
Ton and Joe Webb
Heather Webb
Johannes Weber
Dan Weinberg
Dana Weinstein
Eric Weiss
Meredith Welch
Sandhi Wells
Francoise Werz
Michael Werner
Donna West
Colleen Westervelt
Maryjane Wheble
Margaret and Jerry Whitaker
Otis White
Thomas Whiteley
Jeffrey Wichmann
Joseph Wilkes
Betsy Wilkinson
Mary and Joseph Wiley
Robert Williams
Tom Williams
Denise Willoughby
Scott Wilson
Loretta and Bob Wilson
Andrea and Larry Wine
LySaundra Winstead
Brian Wolfe
Scott Woodworth
Russell Wyman
Gio Yahima
Susan Yamanka
YourCause LLC
Maria Zamora
Marc and Marcia Zanger
Michael Zicari
Thomas Zielonka
Tony Zumbo
Richard Zytkowicz
Board of Directors

Debra Black, Chair
Co-Founder, MRA; Broadway Producer, Phaidon Press; Melanoma Survivor

Leon Black
Co-Founder, MRA; Board Member, FasterCures; CEO, Apollo Management LP

Maria Bell
Television Writer and Producer

Ellen Davis
Founder and Chairman of the Board, JCC Greenwich; President, UJA Greenwich

Amanda Eilian
Co-Founder and President, Videolicious (The Talk Market Inc.)

Jason Federici
Art Director, Graphic Designer, Photographer

Jami Gertz
Television Writer and Producer

Susan Hess
Vice Chairman, Whitney Museum

Michael Klowden
President and CEO, Milken Institute

Nancy Marks
Chairman, Ralph Rucci
Philanthropist

Cindy Hensley McCain
Humanitarian and Businesswoman

Michael Milken
Chairman; Milken Institute; Founder and Chairman, Prostate Cancer Foundation

Richard Ressler
Founder, Orchard Capital Corporation and CIM Group

Mary Jo Rogers
Melanoma Patient and Advocate

Jeffrey Rowbottom
Managing Director, PSP Investments

Elliott Sigal, M.D., Ph.D
Former Executive Vice President & Chief Scientific Officer, Bristol-Myers Squibb

Gregory C. Simon
Chief Executive Officer, Poliwogg

Jonathan W. Simons, M.D.
President and CEO, David H. Koch Chair, Prostate Cancer Foundation

Jonathan Sokoloff
Managing Partner, Leonard Green & Partners, LP

Elizabeth Stanton
President, Oliver and Elizabeth Stanton Foundation

Suzanne L. Topalian, M.D.
Professor, Surgery and Oncology, Johns Hopkins University School of Medicine

Kamyab Hashemi-Nejad, Treasurer
Director of Finance, Milken Institute

Connie Mack (Emeritus member)
Senior Policy Advisor, Liberty Partners Group LLC
Former U.S. Senator

Suzanne Topalian, M.D., Chair
Johns Hopkins University School of Medicine

Richard Gaynor, M.D.
Eli Lilly and Company

Michael Giordano, M.D.
Bristol-Myers Squibb

Allan Halpern, M.D.
Memorial Sloan Kettering Cancer Center

Axel Hoos, M.D., Ph.D.
GlaxoSmithKline

Jeffrey Legos, Ph.D.
Novartis Pharmaceuticals Corporation

Richard Marais, Ph.D.
Cancer Research UK Manchester Institute

Ira Mellman, Ph.D.
Genentech

David Reese, M.D.
Amgen, Inc.

Neal Rosen, M.D., Ph.D.
Memorial Sloan Kettering Cancer Center

Steven Rosen, M.D.
National Cancer Institute
* Dr. Rosenberg serves on the MRA Scientific Advisory Panel in his personal capacity.

Eric Rubin, M.D.
Merck Research Laboratories

Ellen Sigal, Ph.D
Friends of Cancer Research

Steven Stein, M.D.
Incyte

Michael Weber, Ph.D.
University of Virginia

Committees

Scientific Advisory Panel (2015)

The Scientific Advisory Panel advises the MRA leadership team on scientific matters and policies of MRA, including research needs and opportunities that may be targeted for funding and planning scientific symposia.

Michael Giordano, M.D.
Bristol-Myers Squibb

Allan Halpern, M.D.
Memorial Sloan Kettering Cancer Center

Axel Hoos, M.D., Ph.D.
GlaxoSmithKline

Jeffrey Legos, Ph.D.
Novartis Pharmaceuticals Corporation

Richard Marais, Ph.D.
Cancer Research UK Manchester Institute

Ira Mellman, Ph.D.
Genentech

David Reese, M.D.
Amgen, Inc.

Neal Rosen, M.D., Ph.D.
Memorial Sloan Kettering Cancer Center

Steven Rosen, M.D.
National Cancer Institute
* Dr. Rosenberg serves on the MRA Scientific Advisory Panel in his personal capacity.

Eric Rubin, M.D.
Merck Research Laboratories

Ellen Sigal, Ph.D
Friends of Cancer Research

Steven Stein, M.D.
Incyte

Michael Weber, Ph.D.
University of Virginia
Grant Review Committee (2015)

The Grant Review Committee provides scientific merit-based peer review of research proposals submitted to MRA. The committee also advises MRA on other scientific matters as requested.

Levi Garraway, M.D., Ph.D., Chair
Dana-Farber Cancer Institute

Antoni Ribas, M.D., Ph.D., Co-Chair
University of California, Los Angeles

Andrew Aplin, Ph.D.
Thomas Jefferson University

Marcus Rosenberg, M.D., Ph.D.
Yale School of Medicine

Steven Burakoff, M.D.
Icahn School of Medicine at Mount Sinai

Paul B. Chapman, M.D.
Memorial Sloan Kettering Cancer Center

Tanja de Gruijl, Ph.D.
VU University Medical Center, Amsterdam

Charles G. Drake, M.D., Ph.D.
Johns Hopkins University School of Medicine

David Fisher, M.D., Ph.D.
Massachusetts General Hospital

Keith Flaherty, M.D.
Massachusetts General Hospital

Medical Advisory Panel (2015)

The Medical Advisory Panel advises the MRA leadership team on medical matters and policies including clinical research needs and opportunities, clinical regulatory and policy initiatives, and public education about melanoma.

Dermatology

David Fisher, M.D., Ph.D.
Massachusetts General Hospital
Harvard Medical School

Sancy Leachman, M.D., Ph.D.
Oregon Health and Science University

Roger Lo, M.D., Ph.D.
University of California, Los Angeles

Medical Oncology

Michael Atkins, M.D.
Georgetown University

Paul Chapman, M.D.
Memorial Sloan Kettering Cancer Center

Thomas Gajewski, M.D., Ph.D.
University of Chicago

F. Stephen Hodi, M.D.
Harvard Medical School
Dana-Farber Cancer Institute

Patrick Hwu, M.D.
The University of Texas MD Anderson Cancer Center

Surgical Oncology

Charlotte Arians, M.D.
Memorial Sloan Kettering Cancer Center

Jeffrey Gershenwald, M.D.
University of Texas MD Anderson Cancer Center

Suzanne Topalian, M.D.
Johns Hopkins University School of Medicine

MRA Staff

Margaret Anderson
Acting President and CEO

Laura Brockway-Lunardi, Ph.D.
Scientific Program Director

Emily Dammeyer
Director of Communications and Outreach

Logan Downey
Director of Marketing and Development

Jennifer Engel
Development Manager, Foundations and Campaigns

Rachel Gazzaro
Database Manager, CRM and Donor Communications

Lauren C. Leiman
Senior Advisor

Randy Marsh
Executive and Operations Manager

Louise M. Perkins, Ph.D.
Chief Science Officer

Tasheema Prince
Scientific Program Manager
### Statement of Financial Position

**December 31, 2014**  
With Summarized Totals at December 31, 2013

<table>
<thead>
<tr>
<th>Assets</th>
<th>2014</th>
<th>2013</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Unrestricted</td>
<td>Temporarily Restricted</td>
</tr>
<tr>
<td>Cash and Cash Equivalents</td>
<td>$13,143,347</td>
<td>$3,073,360</td>
</tr>
<tr>
<td>Contributions Receivable</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Prepaid Expenses and Other Assets</td>
<td>$37,421</td>
<td>-</td>
</tr>
<tr>
<td>Prepaid and Equipment (Net)</td>
<td>$30,836</td>
<td>-</td>
</tr>
<tr>
<td><strong>Total Assets</strong></td>
<td><strong>$13,211,770</strong></td>
<td><strong>$18,031,782</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Liabilities and Net Assets</th>
<th>2014</th>
<th>2013</th>
</tr>
</thead>
<tbody>
<tr>
<td>Liabilities</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Accounts Payable and Accrued Liabilities</td>
<td>$139,129</td>
<td>-</td>
</tr>
<tr>
<td>Deferred Revenue</td>
<td>152,500</td>
<td>-</td>
</tr>
<tr>
<td>Due to Affiliate</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td><strong>Total Liabilities</strong></td>
<td><strong>291,629</strong></td>
<td>-</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Net Assets</th>
<th>2014</th>
<th>2013</th>
</tr>
</thead>
<tbody>
<tr>
<td>Unrestricted</td>
<td>$12,920,141</td>
<td>-</td>
</tr>
<tr>
<td>Temporarily Restricted</td>
<td>-</td>
<td>$18,031,782</td>
</tr>
<tr>
<td><strong>Total Net Assets</strong></td>
<td><strong>$12,920,141</strong></td>
<td><strong>$18,031,782</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Total Liabilities and Net Assets</th>
<th>2014</th>
<th>2013</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>$13,211,770</strong></td>
<td><strong>$18,031,782</strong></td>
<td><strong>$35,565,902</strong></td>
</tr>
</tbody>
</table>

### Statement of Activities

**Year Ended December 31, 2014**  
With Summarized Totals for the Year Ended December 31, 2013

<table>
<thead>
<tr>
<th>Revenues, Public Support and Other Income</th>
<th>2014</th>
<th>2013</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Unrestricted</strong></td>
<td><strong>Temporarily Restricted</strong></td>
<td><strong>Total</strong></td>
</tr>
<tr>
<td>Contributions</td>
<td>$3,538,446</td>
<td>$2,474,365</td>
</tr>
<tr>
<td>Special Events (Net of Cost of Direct Donor Benefits of $171,183)</td>
<td>1,248,723</td>
<td>-</td>
</tr>
<tr>
<td>Sponsorships</td>
<td>404,600</td>
<td>-</td>
</tr>
<tr>
<td>Interest Income</td>
<td>38,164</td>
<td>-</td>
</tr>
<tr>
<td>In-Kind Contributions</td>
<td>173,452</td>
<td>-</td>
</tr>
<tr>
<td>Other Income</td>
<td>147,143</td>
<td>-</td>
</tr>
<tr>
<td><strong>Net Assets Released from:</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Purpose Restrictions</td>
<td>1,403,294</td>
<td>-</td>
</tr>
<tr>
<td>Time Restrictions</td>
<td>5,517,846</td>
<td>-</td>
</tr>
<tr>
<td><strong>Total Revenues, Public Support and Other Income</strong></td>
<td><strong>12,471,668</strong></td>
<td><strong>(4,446,775)</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Functional Expenses</th>
<th>2014</th>
<th>2013</th>
</tr>
</thead>
<tbody>
<tr>
<td>Program Services</td>
<td>$11,216,208</td>
<td>-</td>
</tr>
<tr>
<td>Management and General</td>
<td>395,417</td>
<td>-</td>
</tr>
<tr>
<td>Fundraising</td>
<td>687,333</td>
<td>-</td>
</tr>
<tr>
<td><strong>Total Functional Expenses</strong></td>
<td><strong>12,298,958</strong></td>
<td>-</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Change in Net Assets</th>
<th>2014</th>
<th>2013</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Unrestricted</strong></td>
<td><strong>Temporarily Restricted</strong></td>
<td><strong>Total</strong></td>
</tr>
<tr>
<td>Net Assets - Beginning of Year</td>
<td>$12,747,431</td>
<td>-</td>
</tr>
<tr>
<td><strong>Net Assets - End of Year</strong></td>
<td><strong>$12,920,141</strong></td>
<td><strong>$18,031,782</strong></td>
</tr>
</tbody>
</table>